<DOC>
	<DOCNO>NCT01857037</DOCNO>
	<brief_summary>Inclusion criterion : - Patients biochemical recurrence ( Phoenix criterion : PSA nadir + 2 ng/ml ) radiation therapy prostate cancer address prostate biopsy OR - Patients referred institution biopsy-proven local recurrence radiation therapy prostate cancer need re-assessment biopsy ( insufficient number biopsy and/or imprecise location positive biopsy and/or questionable diagnostic recurrence ) Study Design : - Included patient undergo endorectal US examination Histoscanning™ acquisition multiparametric ( T2-weighted , diffusion-weighted dynamic contrast-enhanced ) MRI . - Two independent operator separately define suspicious focal lesion Histoscanning™ image MR image . - Random biopsy ( least 2 core ) perform sextant negative Histoscanning™ MRI ; In sextant positive Histoscanning™ and/or MRI , target biopsy perform suspicious part sextant ( least two core per suspicious lesion ) . - Histoscanning™ MRI result compare biopsy result . A total 30 patient include</brief_summary>
	<brief_title>Post-radiation Prostate Cancer Local Recurrences : Detection With Histoscanning™ MRI</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Patients biochemical recurrence ( Phoenix criterion : PSA nadir + 2 ng/ml ) radiation therapy prostate cancer address prostate biopsy OR Patients referred institution biopsyproven local recurrence radiation therapy prostate cancer need reassessment biopsy ( insufficient number biopsy and/or imprecise location positive biopsy and/or questionable diagnostic recurrence ) IRBapproved informed consent sign Contraindication MRI Contraindication endorectal examination Contraindication prostate biopsy History allergy gadolinium chelate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>